Salignostics
Rehovot, Israel· Est.
Israeli startup delivering CE‑approved saliva‑based rapid tests for home and point‑of‑care diagnostics.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Israeli startup delivering CE‑approved saliva‑based rapid tests for home and point‑of‑care diagnostics.
Infectious DiseasesReproductive Health
Technology Platform
Proprietary saliva concentrator, unmasking device, and metered collection system integrated with ultra‑sensitive lateral flow immunoassays for rapid, non‑invasive detection of biomarkers.
Opportunities
Expansion into high‑volume infectious disease panels and multiplexed home‑testing kits can drive significant revenue growth and market penetration.
Risk Factors
Regulatory clearance timelines, competition from established blood‑based rapid tests, and market adoption of saliva specimens pose key risks.
Competitive Landscape
Few competitors offer CE‑approved saliva‑based RDTs; Salignostics differentiates through patented concentration and unmasking technologies that enable reliable, low‑cost testing.